Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IKT 
Inhibikase Therapeutics Inc (IKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 81.94% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.52M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 0.9 | 52 Weeks Range 1.42 - 4.20 | Updated Date 10/17/2025 |
52 Weeks Range 1.42 - 4.20 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.54% | Return on Equity (TTM) -97.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34579456 | Price to Sales(TTM) 1000000 |
Enterprise Value 34579456 | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 2.75 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 74516635 | Shares Floating 24966799 |
Shares Outstanding 74516635 | Shares Floating 24966799 | ||
Percent Insiders 12.99 | Percent Institutions 78.07 |
Upturn AI SWOT
Inhibikase Therapeutics Inc
Company Overview
History and Background
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics to modify the course of Parkinson's disease and related disorders. Founded to address unmet needs in neurodegenerative disease treatment.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Develops small molecule inhibitors targeting protein aggregation in Parkinson's disease and related disorders, aiming to slow disease progression.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and business management, guided by a board of directors. The organizational structure is designed to facilitate efficient research, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- Risuteganib (AT-3): A disease-modifying therapeutic targeting protein aggregation in Parkinson's disease. Currently in clinical trials. Market share is currently 0 as the product is in the clinical phase. Competitors include companies developing symptomatic treatments and disease-modifying therapies for Parkinson's.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and market demand for new therapies. The neurodegenerative disease market is experiencing growth due to aging populations and increased awareness of these conditions.
Positioning
Inhibikase Therapeutics is positioned as a developer of disease-modifying therapies for Parkinson's disease, targeting the underlying causes of the disease. Its competitive advantage lies in its unique approach to inhibiting protein aggregation.
Total Addressable Market (TAM)
The global Parkinson's disease market is expected to reach billions of USD. Inhibikase is positioned to capture a portion of this TAM with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Currently no marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- SNY
- GILD
- ABBV
Competitive Landscape
Inhibikase competes with companies developing both symptomatic treatments and disease-modifying therapies for Parkinson's disease. Its advantage lies in its specific approach to protein aggregation inhibition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by increasing R&D investments and expansion of the clinical pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals, leading to potential commercialization of its therapies.
Recent Initiatives: Recent initiatives include advancing clinical trials for Risuteganib and exploring potential partnerships.
Summary
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing disease-modifying therapies for Parkinson's disease. Its success hinges on the outcome of its clinical trials, and it faces risks associated with regulatory approvals and competition. The company's unique approach to inhibiting protein aggregation gives it a potential edge, but it must manage its limited financial resources carefully. The company has no acquistions at the current time.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibikase Therapeutics Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2020-12-23 | CEO & Director Mr. Mark T. Iwicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.inhibikase.com |
Full time employees 15 | Website https://www.inhibikase.com | ||
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.